Cargando…

Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study

BACKGROUND: M5717 is the first plasmodium translation elongation factor 2 inhibitor to reach clinical development as an antimalarial. We aimed to characterise the safety, pharmacokinetics, and antimalarial activity of M5717 in healthy volunteers. METHODS: This first-in-human study was a two-part, si...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCarthy, James S, Yalkinoglu, Özkan, Odedra, Anand, Webster, Rebecca, Oeuvray, Claude, Tappert, Aliona, Bezuidenhout, Deon, Giddins, Marla J, Dhingra, Satish K, Fidock, David A, Marquart, Louise, Webb, Lachlan, Yin, Xiaoyan, Khandelwal, Akash, Bagchus, Wilhelmina M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612936/ https://www.ncbi.nlm.nih.gov/pubmed/34715032 http://dx.doi.org/10.1016/S1473-3099(21)00252-8

Ejemplares similares

Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
por: Yin, Xiaoyan, et al.
Publicado: (2023)

Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review
por: Shibeshi, Workineh, et al.
Publicado: (2021)

Translation of liver stage activity of M5717, a Plasmodium elongation factor 2 inhibitor: from bench to bedside
por: Khandelwal, Akash, et al.
Publicado: (2022)

Preclinical Antimalarial Combination Study of M5717, a Plasmodium falciparum Elongation Factor 2 Inhibitor, and Pyronaridine, a Hemozoin Formation Inhibitor
por: Rottmann, Matthias, et al.
Publicado: (2020)

Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo‐ and Racemic Praziquantel: Two Phase I Studies
por: Bagchus, Wilhelmina Maria, et al.
Publicado: (2018)

Open-Label, Randomized, Two-Way, Crossover Study Assessing the Bioequivalence of the Liquid Formulation versus the Freeze-Dried Formulation of Recombinant Human FSH and Recombinant Human LH in a Fixed 2:1 Combination (Pergoveris(®)) in Pituitary-Suppressed Healthy Women
por: Bagchus, Wilhelmina, et al.
Publicado: (2018)

The delayed bloodstream clearance of Plasmodium falciparum parasites after M5717 treatment is attributable to the inability to modify their red blood cell hosts
por: Parkyn Schneider, Molly, et al.
Publicado: (2023)

Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study
por: Mahende, Muhidin K., et al.
Publicado: (2021)

Pre-erythrocytic Activity of M5717 in Monotherapy and Combination in Preclinical Plasmodium Infection Models
por: Fontinha, Diana, et al.
Publicado: (2022)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Author Correction: Propensity of selecting mutant parasites for the antimalarial drug cabamiquine
por: Stadler, Eva, et al.
Publicado: (2023)

Single‐dose pharmacokinetic study comparing the pharmacokinetics of recombinant human chorionic gonadotropin in healthy Japanese and Caucasian women and recombinant human chorionic gonadotropin and urinary human chorionic gonadotropin in healthy Japanese women
por: Bagchus, Wilhelmina, et al.
Publicado: (2017)

Antimalarial drug discovery: progress and approaches
por: Siqueira-Neto, Jair L, et al.
Publicado: (2023)

Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia
por: Ménard, Didier, et al.
Publicado: (2019)

Emerging Southeast Asian PfCRT mutations confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine
por: Ross, Leila S., et al.
Publicado: (2018)

Single Ascending Dose Safety and Pharmacokinetics of CDRI-97/78: First-in-Human Study of a Novel Antimalarial Drug
por: Shafiq, N., et al.
Publicado: (2014)

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Atacicept in a Randomized Trial in Healthy Caucasian and Japanese Subjects
por: Willen, Daniela, et al.
Publicado: (2019)

Nitric Oxide Release from Polydimethylsiloxane-based Polyurethanes
por: Nguyen, Evelyne B., et al.
Publicado: (2014)

Combining Stage Specificity and Metabolomic Profiling to Advance Antimalarial Drug Discovery
por: Murithi, James M., et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Residual Bioprosthetic Valve Immunogenicity: Forgotten, Not Lost
por: Human, Paul, et al.
Publicado: (2022)

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
por: McCarthy, James S, et al.
Publicado: (2017)

Prioritization of Molecular Targets for Antimalarial Drug Discovery
por: Forte, Barbara, et al.
Publicado: (2021)

707. Clarifying the Role of CrrB in Polymxyin-resistant Klebsiella pneumoniae Clinical Isolates Utilizing a Novel CRISPR-Cas9 System
por: McConville, Thomas, et al.
Publicado: (2018)

An efficient and versatile CRISPR-Cas9 system for genetic manipulation of multi-drug resistant Klebsiella pneumoniae
por: McConville, Thomas H., et al.
Publicado: (2021)

Mutant PfCRT Can Mediate Piperaquine Resistance in African Plasmodium falciparum With Reduced Fitness and Increased Susceptibility to Other Antimalarials
por: Wicht, Kathryn J, et al.
Publicado: (2022)

Bicuspid Aortic Valve and Ascending Aortic Aneurysm in a Twin Pregnancy
por: Bryant, Eryn, et al.
Publicado: (2020)

Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials
por: Pitsiu, Maria, et al.
Publicado: (2023)

Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
por: Skinner-Adams, Tina S., et al.
Publicado: (2019)

Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance
por: Burgert, Lydia, et al.
Publicado: (2021)

The antimalarial efficacy and mechanism of resistance of the novel chemotype DDD01034957
por: Miguel-Blanco, Celia, et al.
Publicado: (2021)

An affordable antimalarial.
por: Tenenbaum, David J
Publicado: (2004)

Marine Antimalarials
por: Fattorusso, Ernesto, et al.
Publicado: (2009)

Synthetic Antimalarials
Publicado: (1955)

Structure-Guided Identification of Resistance Breaking Antimalarial N‑Myristoyltransferase Inhibitors
por: Schlott, Anja C., et al.
Publicado: (2019)

Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery
por: Shibeshi, Melkamu Adigo, et al.
Publicado: (2020)

Enron Ascending
por: Bradley, Robert
Publicado: (2018)

The Ascending Spirit
Publicado: (1891)

Cannot write session to /tmp/vufind_sessions/sess_qj1oiqaap691pd6c12bs4r2ms4